RaQualia Pharma Inc. Fundamental Analysis (JPX: 4579.T)
RaQualia Pharma Inc. (JPX: 4579.T) shows weak financial fundamentals with a PE ratio of 63.02, profit margin of 4.13%, and ROE of 2.23%. The company generates $3.7B in annual revenue with strong year-over-year growth of 28.07%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 66.9/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze 4579.T's fundamental strength across five key dimensions:
Efficiency Score
Weak4579.T struggles to generate sufficient returns from assets.
Valuation Score
Weak4579.T trades at a premium to fair value.
Growth Score
Moderate4579.T shows steady but slowing expansion.
Financial Health Score
Excellent4579.T maintains a strong and stable balance sheet.
Profitability Score
Moderate4579.T maintains healthy but balanced margins.
Key Financial Metrics
Is 4579.T Expensive or Cheap?
P/E Ratio
4579.T trades at 63.02 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, 4579.T's PEG of 3.08 indicates potential overvaluation.
Price to Book
The market values RaQualia Pharma Inc. at 1.87 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 18.52 times EBITDA. This signals the market has high growth expectations.
How Well Does 4579.T Make Money?
Net Profit Margin
For every $100 in sales, RaQualia Pharma Inc. keeps $4.13 as profit after all expenses.
Operating Margin
Core operations generate 8.60 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $2.23 in profit for every $100 of shareholder equity.
ROA
RaQualia Pharma Inc. generates $1.46 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
RaQualia Pharma Inc. produces operating cash flow of $469.49M, showing steady but balanced cash generation.
Free Cash Flow
RaQualia Pharma Inc. generates strong free cash flow of $431.27M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $17.63 in free cash annually.
FCF Yield
4579.T converts 3.33% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
63.02
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
3.08
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.87
vs 25 benchmark
P/S Ratio
Price to sales ratio
3.54
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.34
vs 25 benchmark
Current Ratio
Current assets to current liabilities
5.78
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.02
vs 25 benchmark
ROA
Return on assets percentage
0.01
vs 25 benchmark
ROCE
Return on capital employed
0.03
vs 25 benchmark
How 4579.T Stacks Against Its Sector Peers
| Metric | 4579.T Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 63.02 | 32.14 | Worse (Expensive) |
| ROE | 2.23% | 550.00% | Weak |
| Net Margin | 4.13% | 30133.00% | Weak |
| Debt/Equity | 0.34 | 0.56 | Strong (Low Leverage) |
| Current Ratio | 5.78 | 5.70 | Strong Liquidity |
| ROA | 1.46% | 3.00% | Weak |
4579.T outperforms its industry in 2 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews RaQualia Pharma Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
217.89%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
139.80%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
-9.06%
Industry Style: Defensive, Growth, Innovation
Declining